Ill. Man Says Takeda Concealed Gout Drug Uloric’s Cardiovascular Risks

CHICAGO — An Illinois man has sued Takeda Pharmaceuticals in federal court, accusing it of concealing the cardiovascular risks posed by its gout drug Uloric (febuxostat).

The Oct. 28 complaint, filed in the U.S. District Court for the Northern District of Illinois, says Takeda knew but failed to warn doctors and patients that the Uloric poses an increased risk of death drug as compared to competitor drugs.

Uloric is a xanthine oxidase inhibitor, which contains the active ingredient, febuxostat. Febuxostat is designed for patients with hyperuricemia and gout, and also for patients who have exhibited sensitivities to allopurinol. Allopurinol was …